Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2320-2324

  Bessede, T ^a,b   Massard, C ^a   Albouy, B ^a,c   Leborgne, S ^a   Gross Goupil, M ^a   Droupy, S ^d   Patard, J J ^a,b   Fizazi, K ^a   Escudier, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Antiangiogenic; Molecular targeted therapy; Quality of life; Renal clear cell carcinoma; Sexual disorders

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; KIDNEY CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; ORGASM; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80053147912     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq766     Document Type: Article

References (26)

1. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
2. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s-684s.
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
4. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 56(6): 959-971.
5. Haas NB, Uzzo R. Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep 2008; 10: 245-252.
6. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176: 2353-2358.
7. Lindau ST, Schumm LP, Laumann EO et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762-774.
8. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-930.
9. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
10. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
11. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226-244.
12. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
13. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-544.
14. Giuliano F, Chevret-Measson M, Tsatsaris A et al. Prevalence of erectile dysfunction in France: results of an epidemiological survey of a representative sample of 1004 men. Eur Urol 2002; 42: 382-389.
15. Droupy S, Giuliano F, Cuzin B et al. [Prevalence of erectile dysfunction in patients consulting urological clinics: the ENJEU survey (one day national survey on prevalence of male sexual dysfunction among men consulting urologists)]. Prog Urol 2009; 19: 830-838.
16. Johannes CB, Araujo AB, Feldman HA et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460-463.
17. Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among longterm (5+ years) adult cancer survivors. Psychooncology 2007; 16: 691-706.
18. Potosky AL, Reeve BB, Clegg LX et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430-437.
19. Droupy S, Ponsot Y, Giuliano F. How, why and when should urologists evaluate male sexual function? Nat Clin Pract Urol 2006; 3: 84-94.
20. Shell JA. Sexual issues in the palliative care population. Semin Oncol Nurs 2008; 24: 131-134.
21. Vardy J, Wefel JS, Ahles T et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19: 623-629.
22. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17: 351-355.
23. Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet 2007; 369: 597-611.
24. Huyghe E, Zairi A, Nohra J et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20: 305-311.
25. Lee S, Coco M, Greenstein SM et al. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant 2005; 19: 162-167.
26. Krychman ML, Pereira L, Carter J, Amsterdam A. Sexual oncology: sexual health issues in women with cancer. Oncology 2006; 71: 18-25.